Mostrar el registro sencillo del ítem

dc.contributor.authorFauquert, J. L.
dc.contributor.authorAlba-Linero, Carmen 
dc.contributor.authorGherasim, A.
dc.contributor.authorTestera Montes, A.
dc.contributor.authorBentabol-Ramos, G.
dc.contributor.authorSaenz de Santa María-García, Rocío
dc.contributor.authorTorres-Jaén, María Josefa 
dc.contributor.authorEguiluz-Gracia, Ibón
dc.contributor.authorRondon, C.
dc.date.accessioned2023-04-21T10:34:59Z
dc.date.available2023-04-21T10:34:59Z
dc.date.issued2023
dc.identifier.citationFauquert JL, Alba-Linero C, Gherasim A, Testera-Montes A, Bentabol-Ramos G, Saenz de Santa Maria-Garcia R, Torres MJ, Eguiluz-Gracia I, Rondon C. Organ-specific allergen challenges in airway allergy: Current utilities and future directions. Allergy. 2023 Apr 1. doi: 10.1111/all.15731. Epub ahead of print. PMID: 37002709.es_ES
dc.identifier.urihttps://hdl.handle.net/10630/26347
dc.description.abstractAtopy has been long used as the screening method for airway allergy. Nevertheless, aeroallergens can trigger respiratory symptoms not only in atopic patients (atopic res piratory allergy, ARA), but also in non-atopic subjects (local respiratory allergy, LRA). Moreover, ARA and LRA can coexist in the same patient, and this clinical scenario has been called dual respiratory allergy (DRA). When the clinical history cannot determine the relevance of sensitizations in ARA patients, nasal, conjunctival or bronchial aller gen challenges (NAC, CAC, and BAC, respectively) should be conducted. Moreover, these tests are required to identify patients with LRA and DRA. The clarification of the allergic triggers of airway diseases has a profound impact on the management strategies the patients can be offered. Importantly, allergen immunotherapy (AIT) remains as the only disease-modifying intervention for ARA. Recent data indicate that AIT might have a similar effect on LRA patients. Nevertheless, AIT success relies largely on the correct phenotyping of allergic individuals, and NAC, CAC, and BAC are very helpful tools in this regard. In this review, we will summarize the main indications and methodology of CAC, NAC, and BAC. Importantly, the clinical implementation of these tests might translate into precision medicine approaches and better health outcomes for patients with airway allergy.es_ES
dc.description.sponsorshipConsejería de Salud, Junta de Andalucía, Grant/Award Number: P20_00405; Instituto de Salud Carlos III, Grant/Award Number: PI20/01715, RD21/0002/0008, CM21/00262, CM20/00160, JR22/00048 and JR19/00029. Funding for open access charge: Universidad de Málaga / CBUA.es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAlergia-Diagnósticoes_ES
dc.subjectAlergia-Tratamientoes_ES
dc.subject.otherAllergic asthmaes_ES
dc.subject.otherAllergic rhinitises_ES
dc.subject.otherBronchial allergen challengees_ES
dc.subject.otherConjunctival allergen challengees_ES
dc.subject.otherNasal allergen challengees_ES
dc.titleOrgan-specific allergen challenges in airway allergy: Current utilities and future directionses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doihttps://doi.org/10.1111/all.15731
dc.rights.ccAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional